NDAORALTABLET
Approved
Oct 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURON (methyclothiazide) is a thiazide diuretic approved in 1960 for the treatment of hypertension and edema. It works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion to reduce blood pressure and fluid overload. This oral tablet represents a legacy antihypertensive class with decades of clinical use.
LOE Approaching
With LOE approaching and competitive pressure at 30%, this product faces declining revenue trajectory and likely small brand team focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ENDURON offers limited career upside given its LOE-approaching status and minimal linked job openings. This role suits professionals seeking stability in a legacy product portfolio rather than dynamic growth or innovation-driven advancement.
Product ManagerField Sales Representative
Worked on ENDURON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.